InvestorsHub Logo
Followers 15
Posts 221
Boards Moderated 0
Alias Born 05/09/2014

Re: None

Wednesday, 01/20/2016 4:11:49 PM

Wednesday, January 20, 2016 4:11:49 PM

Post# of 14953
SRNE is well positioned with NK agreement 600M to 1.2B as milestones are met. Recent successes in phase III bio-similars in China study only add to SRNE portfolio.

Looking to add during the volatility, but seeking alpha posted a
'Biotech' bounce, buyers quickly appearing in the sector. I don't believe SRNE will trade sub $6 for very long. Oil and materials tumble, bio bounces IMO
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SRNE News